Saruwatari K - Search Results

1

Association of Probiotic Clostridium butyricum Therapy with Survival and Response to Immune Checkpoint Blockade in Patients with Lung Cancer.

Tomita Y, Ikeda T, Sakata S, Saruwatari K, Sato R, Iyama S, Jodai T, Akaike K, Ishizuka S, Saeki S, Sakagami T. Tomita Y, et al. Among authors: saruwatari k. Cancer Immunol Res. 2020 Oct;8(10):1236-1242. doi: 10.1158/2326-6066.CIR-20-0051. Epub 2020 Jul 14. Cancer Immunol Res. 2020. PMID: 32665261

2

Dose escalation and pharmacokinetic study of carboplatin plus pemetrexed for elderly patients with advanced nonsquamous non-small-cell lung cancer: Kumamoto thoracic oncology study group trial 1002.

Sakata S, Sasaki J, Saeki S, Hamada A, Kishi H, Nakamura K, Tanaka H, Notsute D, Sato R, Saruwatari K, Iriki T, Akaike K, Fujii S, Hirosako S, Kohrogi H. Sakata S, et al. Among authors: saruwatari k. Oncology. 2015;88(4):201-7. doi: 10.1159/000369255. Epub 2014 Dec 6. Oncology. 2015. PMID: 25502447

3

Acute coronary syndrome as a possible immune-related adverse event in a lung cancer patient achieving a complete response to anti-PD-1 immune checkpoint antibody.

Tomita Y, Sueta D, Kakiuchi Y, Saeki S, Saruwatari K, Sakata S, Jodai T, Migiyama Y, Akaike K, Hirosako S, Fujisue K, Yamamura S, Miyazaki S, Takashio S, Izumiya Y, Nakamura K, Tsujita K, Ichiyasu H, Fujii K. Tomita Y, et al. Among authors: saruwatari k. Ann Oncol. 2017 Nov 1;28(11):2893-2895. doi: 10.1093/annonc/mdx326. Ann Oncol. 2017. PMID: 28651328 Free article. No abstract available.

4

Trousseau's syndrome triggered by an immune checkpoint blockade in a non-small cell lung cancer patient.

Horio Y, Takamatsu K, Tamanoi D, Sato R, Saruwatari K, Ikeda T, Nakane S, Nakajima M, Saeki S, Ichiyasu H, Fujii K, Tomita Y. Horio Y, et al. Among authors: saruwatari k. Eur J Immunol. 2018 Oct;48(10):1764-1767. doi: 10.1002/eji.201847645. Epub 2018 Jul 19. Eur J Immunol. 2018. PMID: 29981156 Free article.

5

Negative Impact of Coexisting Interstitial Lung Disease on Clinical Outcomes in Small-cell Lung Cancer Patients.

Akaike K, Saruwatari K, Okabayashi H, Hamada S, Jodai Y, Jodai T, Sakata S, Iyama S, Sato R, Iriki T, Tomita Y, Saeki S, Ichiyasu H, Fujii K. Akaike K, et al. Among authors: saruwatari k. Anticancer Res. 2018 Nov;38(11):6543-6550. doi: 10.21873/anticanres.13020. Anticancer Res. 2018. PMID: 30396984

6

A potential mechanism of the onset of acute eosinophilic pneumonia triggered by an anti-PD-1 immune checkpoint antibody in a lung cancer patient.

Jodai T, Yoshida C, Sato R, Kakiuchi Y, Sato N, Iyama S, Kimura T, Saruwatari K, Saeki S, Ichiyasu H, Fujii K, Tomita Y. Jodai T, et al. Among authors: saruwatari k. Immun Inflamm Dis. 2019 Mar;7(1):3-6. doi: 10.1002/iid3.238. Epub 2018 Nov 21. Immun Inflamm Dis. 2019. PMID: 30461210 Free PMC article.

7

The Risks and Benefits of Immune Checkpoint Blockade in Anti-AChR Antibody-Seropositive Non-Small Cell Lung Cancer Patients.

Saruwatari K, Sato R, Nakane S, Sakata S, Takamatsu K, Jodai T, Mito R, Horio Y, Saeki S, Tomita Y, Sakagami T. Saruwatari K, et al. Cancers (Basel). 2019 Jan 24;11(2):140. doi: 10.3390/cancers11020140. Cancers (Basel). 2019. PMID: 30682845 Free PMC article.

8

Upfront Cranial Radiotherapy Followed by Erlotinib Positively Affects Clinical Outcomes of Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer With Brain Metastases.

Saruwatari K, Ikeda T, Saeki S, Shingu N, Imamura K, Komatu T, Ushijima S, Maruyama H, Kashiwabara K, Tomita Y, Ichiyasu H, Fujii K, Sakagami T. Saruwatari K, et al. Anticancer Res. 2019 Feb;39(2):923-931. doi: 10.21873/anticanres.13195. Anticancer Res. 2019. PMID: 30711977

9

Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer.

Hamada S, Ichiyasu H, Ikeda T, Inaba M, Kashiwabara K, Sadamatsu T, Sato N, Akaike K, Okabayashi H, Saruwatari K, Tomita Y, Saeki S, Hirata N, Yoshinaga T, Fujii K. Hamada S, et al. Among authors: saruwatari k. BMC Pulm Med. 2019 Apr 2;19(1):72. doi: 10.1186/s12890-019-0838-2. BMC Pulm Med. 2019. PMID: 30940113 Free PMC article.

10

Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies.

Sato R, Imamura K, Sakata S, Ikeda T, Horio Y, Iyama S, Akaike K, Hamada S, Jodai T, Nakashima K, Ishizuka S, Sato N, Saruwatari K, Saeki S, Tomita Y, Sakagami T. Sato R, et al. Among authors: saruwatari k. J Clin Med. 2019 May 29;8(6):762. doi: 10.3390/jcm8060762. J Clin Med. 2019. PMID: 31146442 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

72 results

Search Page